Lifesci Capital Reiterates “Market Perform” Rating for Ventyx Biosciences (NASDAQ:VTYX)

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “market perform” rating reaffirmed by analysts at Lifesci Capital in a research note issued on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock. Lifesci Capital’s target price would indicate a potential upside of 1.38% from the company’s current price.

A number of other equities analysts have also issued reports on VTYX. UBS Group reissued a “neutral” rating and set a $14.00 price target (down previously from $20.00) on shares of Ventyx Biosciences in a report on Thursday. Wells Fargo & Company boosted their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Canaccord Genuity Group downgraded Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $16.00 to $14.00 in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Finally, HC Wainwright upgraded shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $14.86.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $13.81 on Thursday. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $25.00. The stock has a market cap of $985.48 million, a PE ratio of -9.21 and a beta of 1.23. The firm has a fifty day moving average price of $9.27 and a 200 day moving average price of $5.28.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. As a group, equities analysts expect that Ventyx Biosciences will post -2.09 EPS for the current fiscal year.

Insider Buying and Selling at Ventyx Biosciences

In other news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the transaction, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 14.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of VTYX. Affinity Asset Advisors LLC purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter worth approximately $9,707,000. Vanguard Group Inc. raised its holdings in Ventyx Biosciences by 19.2% during the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after purchasing an additional 607,725 shares during the last quarter. Marshall Wace LLP purchased a new stake in Ventyx Biosciences during the second quarter worth $5,129,000. Vestal Point Capital LP grew its holdings in Ventyx Biosciences by 2.5% in the third quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock valued at $6,376,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Ventyx Biosciences by 17.5% in the third quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock valued at $5,137,000 after buying an additional 246,040 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Ventyx Biosciences

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.